Investigating the mechanisms of hyporesponse to antiplatelet approaches

Clinical Cardiology

Volumn 31, Issue 3 SUUPL. 1, 2008, Pages

  Braunwald, Eugene ^a   Angiolillo, Dominick ^b   Bates, Eric ^c   Berger, Peter B ^d   Bhatt, Deepak ^e   Cannon, Christopher P ^a   Furman, Mark I ^f   Gurbel, Paul ^g   Michelson, Alan D ^h   Peterson, Eric ⁱ   Wiviott, Stephen ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^d GEISINGER MEDICAL CENTER   (United States)

^e LERNER RESEARCH INSTITUTE   (United States)

^f South Shore Hospital   (United States)

^g JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

ⁱ DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Acute coronary syndromes

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; INSULIN;

ACUTE CORONARY SYNDROME; BLEEDING; BLOOD CLOTTING PARAMETERS; BODY MASS; CLINICAL TRIAL; CONFERENCE PAPER; CORONARY ARTERY DISEASE; DIABETIC PATIENT; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MECHANISM; GENETIC POLYMORPHISM; HEART CATHETERIZATION; HEREDITY; HUMAN; INSULIN TREATMENT; LOADING DRUG DOSE; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS;

ASPIRIN; BLOOD PLATELETS; DRUG RESISTANCE; DRUG THERAPY, COMBINATION; GENETIC PREDISPOSITION TO DISEASE; HUMANS; PATIENT SELECTION; PLATELET AGGREGATION INHIBITORS; PLATELET FUNCTION TESTS; RISK ASSESSMENT; RISK FACTORS; TICLOPIDINE; TREATMENT OUTCOME;

EID: 41149124824     PISSN: 01609289     EISSN: None     Source Type: Journal    
DOI: 10.1002/clc.20360     Document Type: Conference Paper

References (42)

1. Antithrombotic Trialists Collaboration: Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002;324:71-86
2. The Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators: Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-elevation. N Engl J Med 2001;345:494-502
3. Chen ZM, Jiang LX, Chen YP, Xie JX, Pan HC, for the COMMIT (ClOpidogrel and Metoprolol in Myocardial Infarction Trial) collaborative group: Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomized placebo controlled trial. Lancet 2005;366:1607-1621
4. Steinhubl SR, Berger PB, Mann JT HI, Fry ETA, DeLago A, et al.: Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial JAMA 2002;288:2411-2420
5. Sabatine MS, Cannon CP, Gibson CM, López-Sendón JL, Montalescot G, et al.: Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med 2005;352:1179-1189
6. Eikelboom JW, Hirsh J, Weitz JI, Johnston M, Yi Q, et al.: Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, of cardiovascular death in patients at high risk for cardiovascular events. Circulation 2002;105:1650-1655
7. Chen WH, Lee PY, Ng W, Tse HF, Lau CP: Aspirin resistance is associated with a high incidence of myonecrosis after non-urgent percutaneous coronary intervention despite clopidogrel pretreatment. J Am Coll Cardiol 2004;43:1122-1126
8. Bhatt DL: Aspirin resistance: more than just a laboratory curiosity. J Am Coll Cardiol 2004;43:1127-1129
9. Frelinger AL 3rd, Furman MI, Linden MD, Li Y, Fox ML, et al.: Residual arachidonic acid-induced platelet activation via an adenosine diphosphate-dependent but cyclooxygenase-1- and cyclooxygenase-2-independent pathway: a 700-patient study of aspirin resistance. Circulation 2006;113:2888-2896
10. Gurbel PA, Bliden KP, DiChiara J, Newcomer J, Weng W, et al.: Evaluation of dose-related effects of aspirin on platelet function: results from the Aspirin-induced Platelet Effect study. Circulation 2007;115:3156-3164
11. Catella-Lawson F, Reilly MP, Kapoor SC, Cucchiara AJ, DeMarco S, et al.: Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med 2001;345:1809-1817
12. Peters RJG, Mehta SR, Fox KAA, Zhao F, Lewis BS, For the Clopidogrel in Unstable Angina to Prevent Recurrent Events (CURE) trial: Effects of aspirin dose when used alone or in combination with clopidogrel in patients with acute coronary syndromes: observations from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study. Circulation 2003;108:1682-1687
13. Topol EJ, Kaston D, Harrington RA, Amarenco P, Califf KM, et al.: Randomized, double-blind, placebo-controlled, international trial of the oral IIb/IIIa antagonist lotrafiban in coronary and cerebrovascular disease. Circulation 2003;108:399-406
14. Macchi L, Christiaens L, Brabant S, Sorel N, Allal J, et al.: Resistance to aspirin in vitro is associated with increased platelet sensitivity to adenosine diphosphate. Thromb Res 2002;107:45-49
15. Järemo P, Lindahl TL, Fransson SG, Richter A: Individual variations of platelet inhibition after loading doses of clopidogrel. J Intern Med 2002;252:233-238
16. Gurbel PA, Bliden KP, Hiatt BL, O'Connor CM: Clopidogrel for coronary stenting: response variability, drug resistances, and the effect of pretreatment platelet reactivity. Circulation 2003;107:2908-2913
17. Gurbel PA: The relationship of platelet reactivity to the occurrence of post-stenting ischemic events: emergence of a new cardiovascular risk factor. Rev Cardiovasc Med 2006;7:S20-S28
18. Matetzky S, Shenkman B, Guetta V, Shecter M, Bienart R, et al.: Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation 2004;109:3171-3175
19. Müller I, Besta F, Schulz C, Massberg S, Schönig A, et al.: Prevalence of clopidogrel non-responders among patients with stable angina pectoris scheduled for elective coronary stent placement. Thromb Haemost 2003;89:783-787
20. Gurbel PA, Bliden KP: The stratification of platelet reactivity and activation in patients with stable coronary artery disease on aspirin therapy. Thromb Res 2003;112:9-12
21. Samara WM, Bliden KP, Tantry US, Gurbel PA: The difference between clopidogrel responsiveness and posttreatment platelet reactivity. Thromb Res 2005;115:89-94
22. Bliden KP, DiChiara J, Tantry US, Bassi AK, Chaganti SK, et al.: Increased risk in patients with high platelet aggregation receiving chronic clopidogrel therapy undergoing percutaneous coronary intervention: Is the current antiplatelet therapy adequate? J Am Coll Cardiol 2007;49:657-666
23. Wang TH, Bhatt DL, Topol EJ: Aspirin and clopidogrel resistance: an emerging clinical entity. Eur Heart J 2006;27:647-654
24. Hochholzer W, Trenk D, Bestehorn HP, Fischer B, Valina CM, et al.: Impact of the degree of peri-interventional platelet inhibition after loading with clopidogrel on early clinical outcome of elective coronary stent placement. J Am Coll Cardiol 2006;48: 1742-1750
25. Cuisset T, Frere C, Quilici J, Morange P-E, Nait-Saidi L, et al.: Benefit of a 600-mg loading dose of clopidogrel on platelet reactivity and clinical outcomes in patients with non-ST-segment elevation acute coronary syndrome undergoing coronary stenting. J Am Coll Cardiol 2006;48:1339-1345
26. Lau WC, Waskell LA, Watkins PB, Neer CJ, Horowitz K, et al.: Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation: a new drug-drug interaction. Circulation 2003;107:32-37
27. Clarke TA, Waskell LA: The metabolism of clopidogrel is catalyzed by human cytochrome P45 3A and is inhibited by atorvastatin. Drug Metab Dispos 2003;31:53-59
28. Lau WC, Gurbel PA, Watkins PB, Neer CJ, Hopp AS, et al.: Contribution of hepatic cytochrome P450 3A4 metabolic activity to the phenomenon of clopidogrel resistance. Circulation 2004;109:166-171
29. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, Ramirez C, Cavallari U, et al.: Contribution of gene sequence variations of the hepatic cytochrome P450 3A4 enzyme to variability in individual responsiveness to clopidogrel. Arterioscler Thromb Vasc Biol 2006;26:1895-1900
30. Hulot JS, Bura A, Billard E, Azizi M, Remones V, et al.: Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects. Blood 2006;108:2244-2247
31. Gurbel PA, Bliden KP, Hiatt BL, O'Connor CM: Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation 2003;107:2908-2913
32. Soffer D, Moussa I, Harjai KJ, Boura JA, Dixon SR, et al.: Impact of angina class on inhibition of platelet aggregation following clopidogrel loading in patients undergoing coronary intervention: do we need more aggressive dosing regimens in unstable angina? Catheter Cardiovasc Intern 2003;59:21-25
33. Ferreira IA, Mocking AIM, Feijge MAH, Gorter G, van Haeften TW, et al.: Platelet inhibition by insulin is absent in type 2 diabetes mellitus. Arterioscler Thromb Vasc Biol 2006;26:417-422
34. Ferroni P, Basili S, Falco A, Davi G: Platelet activation in type 2 diabetes mellitus. J Thromb Haemost 2004;2:1282-1291
35. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, Ramirez C, Sabaté M, et al.: Platelet function profiles in patients with type 2 diabetes and coronary artery disease on combined aspirin and clopidogrel treatment. Diabetes 2005;54:2430-2435
36. Angiolillo DJ, Bernardo E, Ramirez C, Costa MA, Sabaté M, et al.: Insulin therapy is associated with platelet dysfunction in patients with type 2 diabetes mellitus on dual oral antiplatelet treatment. J Am Coll Cardiol 2006;48:298-304
37. Geisler T, Langer H, Wydymus M, Gohring K, Zurn C, et al.: Low response to clopidogrel is associated with cardiovascular outcome after coronary stent implantation. Eur Heart J 2006;27: 2420-2425
38. Geisler T, Anders N, Paterok M, Langer H, Stellos K, et al.: Platelet response to clopidogrel is attenuated in diabetic patients undergoing coronary stent implantation. Diabetes Care 2007;30:372-374
39. Angiolillo DJ. Fernandez-Ortiz A, Bernardo E, Ramirez C, Sabaté M, et al.: Platelet aggregation according to body mass index in patients undergoing coronary stenting: should clopidogrel loading-dose be weight adjusted? J Invasive Cardiol 2004;16:169-174
40. Sibbing D, von Beckerath O, Schömig A, Kastrati A, von Beckerath N: Impact of body mass index on platelet aggregation after administration of a high loading dose of 600 mg of clopidogrel before percutaneous coronary intervention. Am J Cardiol 2007;100:203-205
41. Lepäntalo A, Virtanen KS, Heikkilä J, Wartiovaara U, Lassila R: Limited early antiplatelet effect of 300 mg clopidogrel in patients with aspirin therapy undergoing percutaneous coronary interventions. Eur Heart J 2004;25:467-483
42. Lev EI, Patel RT, Maresh KJ, Guthikonda S, Granada J, et al.: Aspirin and clopidogrel drug response in patients undergoing percutaneous coronary intervention: the role of dual drug resistance. J Am Coll Cardiol 2006;47:27-33